If you've stood at a pharmacy counter recently and been told Lantus isn't available, you're not imagining it, and you're not alone. But the situation is more specific than a blanket "shortage" headline suggests — it's concentrated in one product format, traced to one clear cause, and it comes with real alternatives that are currently in stock. This guide breaks down exactly what's happening, why, and what to actually do about it if you're standing in front of an empty shelf right now.
1. Is Lantus Officially "In Shortage"?
Technically, no. As of this update, Lantus does not appear on the FDA's official Drug Shortages Database. That distinction matters for insurance and pharmacy processes, but it doesn't change what patients are actually experiencing at the counter.
Sanofi's own statement, provided to STAT News and WRAL on July 23, 2026, describes the situation as "a period of intermittent supply" of the Lantus SoloStar pen specifically, driven by "broader market dynamics." The company called it a temporary situation it expects to improve over the coming weeks, and said its priority is ensuring patients have access to their medication.
In plain terms: this is a real, practical supply problem for many patients, even though it doesn't meet the FDA's formal shortage criteria — a distinction that matters for the paperwork, not for whether you can actually get your prescription filled this week.
2. Why This Is Happening: The Semglee Domino Effect
The immediate cause is demand, not a manufacturing failure at Sanofi. It traces back to a biosimilar insulin that many patients had switched to over the past several years.
Semglee (insulin glargine-yfgn), made by Biocon and marketed by Viatris, was the first FDA-approved interchangeable biosimilar to Lantus, approved in 2021. Over 2022-2024, it gained significant market share as insurance formularies increasingly preferred it as the lower-cost option. Then, on December 31, 2025, Biocon permanently discontinued Semglee entirely — both vials and pens. Millions of patients who had been using Semglee needed to switch to a different insulin glargine product almost overnight, and that sudden demand shift is exactly what's straining Lantus SoloStar pen supply right now.
3. Timeline: How We Got Here
| Date | Event |
|---|---|
| 2021 | FDA approves Semglee as the first interchangeable biosimilar to Lantus |
| 2022-2024 | Semglee gains significant market share; many formularies prefer it |
| 2023 | Sanofi announces a 78% Lantus list price cut, effective 2024, plus a $35/month out-of-pocket cap for commercially insured patients |
| Mid-2025 | Semglee begins experiencing its own supply constraints |
| August 2025 | Regional Semglee shortages intensify, especially in the Pacific Northwest and Northeast |
| December 31, 2025 | Biocon formally discontinues Semglee entirely |
| Jan-March 2026 | Demand shifts to brand Lantus, Basaglar, Rezvoglar, and generic insulin glargine; insurers update formularies |
| July 2026 | Sanofi confirms intermittent supply of Lantus SoloStar pens specifically |
4. Current Availability by Product
| Product | Manufacturer | Status |
|---|---|---|
| Lantus vials | Sanofi | In production; generally available |
| Lantus SoloStar pens | Sanofi | Intermittent back order; releasing supply as available |
| Basaglar | Eli Lilly | Available |
| Basaglar Tempo pens | Eli Lilly | Being discontinued; available only through July 27, 2026 |
| Rezvoglar | Eli Lilly | Available |
| Toujeo / Toujeo Max | Sanofi | Available (different concentration than Lantus) |
| Insulin glargine-yfgn (Semglee) | Biocon | Discontinued as of December 31, 2025 |
5. Alternatives: What's Actually in Stock
If your regular Lantus pen isn't available, several other insulin glargine products are currently on shelves. None of these are automatically interchangeable at the pharmacy counter the way Semglee was explicitly designated — a new prescription or prescriber approval is typically needed to switch.
| Alternative | Concentration | Key consideration |
|---|---|---|
| Basaglar | 100 units/mL (same as Lantus) | Same active ingredient and concentration; often a straightforward switch under medical guidance |
| Rezvoglar | 100 units/mL (same as Lantus) | Another Eli Lilly insulin glargine option at the same concentration |
| Toujeo | 300 units/mL (three times more concentrated) | Not a 1:1 unit swap — requires prescriber-guided dose adjustment |
| Generic insulin glargine vials (other manufacturers) | Typically 100 units/mL | Availability varies by region and pharmacy |
6. Switching Insulin Products Safely
Never switch between insulin products on your own, even between two products that sound similar. Toujeo's higher concentration means the same number of "units" delivers a different physical volume than Lantus, and even switching between same-concentration products like Basaglar or Rezvoglar should be confirmed with your prescriber first, particularly if your dose or timing has ever been adjusted. Call your prescriber's office before your next fill if you know your usual product is hard to find, rather than waiting until you're at the pharmacy counter with no medication in hand.
7. Step-by-Step: What to Do If Your Pharmacy Is Out
Call ahead before your next fill
Call your pharmacy a few days before you need a refill to check current stock, rather than discovering the problem when you arrive.
Check nearby pharmacies
Availability varies significantly by location and even by chain, so a nearby pharmacy may have stock when your regular one doesn't.
Contact your prescriber's office proactively
Let your prescriber know your usual product is unavailable before you run out, so they have time to consider an alternative prescription rather than making the decision at the last minute.
Confirm insurance coverage for the alternative
Call your insurer or check your plan's current formulary before filling a substitute, since coverage tiers have been actively changing since Semglee's discontinuation.
Never skip or ration doses to stretch supply
If you're genuinely at risk of running out, contact your prescriber or pharmacist immediately rather than reducing your dose on your own — insulin dosing errors carry serious health risks.
8. Cost: Sanofi's $35 Cap Still Applies
Separate from the availability issue, Sanofi's 2023 pricing commitment is still in effect: Lantus carries a 78% list price cut effective 2024, and commercially insured patients can access a savings program capping out-of-pocket costs at $35 per month. If you switch to an alternative product because Lantus is unavailable, check that product's own manufacturer savings program separately, since pricing and caps aren't identical across Basaglar, Rezvoglar, and Toujeo.
9. Decision Tree: What Should You Do Right Now?
If you're at risk of running out, don't wait — reach your care team the same day rather than rationing doses or going without.